Twitter LinkedIn
    Saturday, March 25
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Deals & Transactions»Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug
    Deals & Transactions

    Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug

    March 3, 20211 Min Read
    LinkedIn Facebook Twitter Email WhatsApp
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Germany’s Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer.

    Under the terms of the licensing deal, Merck will pay Debiopharm 188 million euros upfront and has agreed to further regulatory and commercial milestones worth up to 710 million euros, as well as royalties.

    Results of a mid-stage study found Xevinapant together with chemoradiotherapy cut the risk of death by 51% compared to the current standard of care, Merck said.

    Read more at: Reuters

    By Caroline Copley and Riham Alkousaa

    Image Source

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    deals
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Thyssenkrupp shares move higher on report of CVC interest in steel unit

    March 21, 2023

    BlackRock Not Working on Rival Bid for Credit Suisse

    March 18, 2023

    University of California invests $4 bn in redemption-stricken REIT

    January 3, 2023

    Warburg Pincus acquires K2 Insurance Services from Lee Equity Partners

    December 6, 2022

    Comments are closed.

    Other Articles

    Onex acquires Falcon Investment Advisors

    December 30, 2020

    Apollo’s $3.9 Billion Brightspeed LBO debt is finding few takers

    September 29, 2022

    Apollo readies Japan private equity push, joining KKR and Carlyle

    December 28, 2020

    Global software sector sees deals worth $130B in Q2

    August 3, 2022

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?